CLYM · Climb Bio Inc. Common Stock
View on chartInsiders & Stakes
| Stephen Basil Thomas | ▼ Sell | Open Market | 467,969 Shares held | 9/15/2026 | View profile |
| Aoife Brennan President and CEO | ▼ Sell | Open Market | 87,731 Shares held | 6/29/2026 | View profile |
| RA CAPITAL MANAGEMENT, L.P. Director | ▲ Buy | Option Exercise | 70,000 Shares held | 9/28/2026 | View profile |
| Morisset Valerie EVP, R&D and CSO | ▼ Sell | Open Market | 31,317 Shares held | 7/22/2024 | View profile |
| Emily Pimblett CHIEF ACCOUNTING OFFICER | ▼ Sell | Open Market | 18,888 Shares held | 6/20/2025 | View profile |
Transaction History
| RA CAPITAL MANAGEMENT, L.P. | ▲ Buy | Option Exercise | 10,000 | $35K | 9/28/2026 |
| RA CAPITAL MANAGEMENT, L.P. | ▲ Buy | Option Exercise | 10,000 | $30K | 9/28/2026 |
| RA CAPITAL MANAGEMENT, L.P. | ▲ Buy | Option Exercise | 10,000 | $79K | 9/28/2026 |
| RA CAPITAL MANAGEMENT, L.P. | ▲ Buy | Option Exercise | 40,000 | $52K | 9/28/2026 |
| Stephen Basil Thomas | ▼ Sell | Open Market | 100,000 | $1.4M | 9/15/2026 |
| Aoife Brennan | ▼ Sell | Open Market | 30,902 | $407K | 6/29/2026 |
| Aoife Brennan | ▲ Buy | Option Exercise | 68,750 | — | 6/27/2026 |
| Stephen Basil Thomas | ▼ Sell | Open Market | 16,313 | $114K | 2/26/2026 |
| Stephen Basil Thomas | ▼ Sell | Open Market | 33,687 | $236K | 2/25/2026 |
| Stephen Basil Thomas | ▼ Sell | Open Market | 10,000 | $58K | 2/13/2026 |
| Stephen Basil Thomas | ▼ Sell | Open Market | 90,000 | $471K | 2/12/2026 |
| RA CAPITAL MANAGEMENT, L.P. | ▲ Buy | Open Market | 7,111 | $25K | 1/5/2026 |
| RA CAPITAL MANAGEMENT, L.P. | ▲ Buy | Open Market | 101,462 | $290K | 12/12/2025 |
| RA CAPITAL MANAGEMENT, L.P. | ▼ Sell | Other | 20,440,000 | $0 | 12/11/2025 |
| RA CAPITAL MANAGEMENT, L.P. | ▲ Buy | Open Market | 213,099 | $465K | 12/11/2025 |
| Stephen Basil Thomas | ▲ Buy | Grant | 100,375 | $0 | 8/7/2025 |
| Aoife Brennan | ▼ Sell | Open Market | 20,618 | $25K | 6/30/2025 |
| Aoife Brennan | ▲ Buy | Option Exercise | 68,750 | — | 6/27/2025 |
| Stephen Basil Thomas | ▲ Buy | Option Exercise | 25,094 | — | 6/27/2025 |
| Emily Pimblett | ▼ Sell | Open Market | 1,242 | $2K | 6/20/2025 |
| Emily Pimblett | ▲ Buy | Option Exercise | 5,000 | — | 6/18/2025 |
| Stephen Basil Thomas | ▲ Buy | Option Exercise | 25,093 | — | 3/27/2025 |
| Emily Pimblett | ▼ Sell | Open Market | 1,199 | $2K | 3/20/2025 |
| Emily Pimblett | ▲ Buy | Option Exercise | 5,000 | — | 3/18/2025 |
| Stephen Basil Thomas | ▲ Buy | Option Exercise | 50,188 | — | 1/1/2025 |
| Emily Pimblett | ▼ Sell | Open Market | 1,235 | $2K | 12/19/2024 |
| Emily Pimblett | ▲ Buy | Option Exercise | 5,000 | — | 12/18/2024 |
| Emily Pimblett | ▼ Sell | Open Market | 1,182 | $10K | 9/20/2024 |
| Emily Pimblett | ▼ Sell | Open Market | 9 | $73 | 9/20/2024 |
| Emily Pimblett | ▲ Buy | Option Exercise | 5,000 | — | 9/18/2024 |
| Morisset Valerie | ▼ Sell | Open Market | 39,005 | $315K | 7/22/2024 |
| Morisset Valerie | ▼ Sell | Open Market | 30,000 | $239K | 7/22/2024 |
| Morisset Valerie | ▼ Sell | Open Market | 10,201 | $72K | 7/19/2024 |
| Morisset Valerie | ▼ Sell | Open Market | 50,000 | $362K | 7/19/2024 |
| Morisset Valerie | ▼ Sell | Open Market | 38,576 | $267K | 7/18/2024 |
| Morisset Valerie | ▼ Sell | Open Market | 3,207 | $22K | 7/17/2024 |
| Morisset Valerie | ▼ Sell | Open Market | 50,000 | $357K | 7/16/2024 |
| Morisset Valerie | ▼ Sell | Open Market | 42,377 | $297K | 7/15/2024 |
| Morisset Valerie | ▼ Sell | Open Market | 50,000 | $354K | 7/12/2024 |
| Morisset Valerie | ▼ Sell | Open Market | 50,000 | $356K | 7/11/2024 |
| Morisset Valerie | ▼ Sell | Open Market | 50,000 | $342K | 7/10/2024 |
| Morisset Valerie | ▼ Sell | Open Market | 5,931 | $40K | 7/9/2024 |
| Morisset Valerie | ▼ Sell | Open Market | 12,342 | $87K | 7/5/2024 |
| Morisset Valerie | ▼ Sell | Open Market | 50,000 | $338K | 7/3/2024 |
| Morisset Valerie | ▲ Buy | Option Exercise | 7,649 | $2 | 7/1/2024 |
| RA CAPITAL MANAGEMENT, L.P. | ▲ Buy | Grant | 2,479,872 | — | 6/27/2024 |
| RA CAPITAL MANAGEMENT, L.P. | ▲ Buy | Grant | 1,807,000 | — | 6/27/2024 |
| RA CAPITAL MANAGEMENT, L.P. | ▲ Buy | Open Market | 1,059,375 | $4.1M | 6/27/2024 |
| Stephen Basil Thomas | ▲ Buy | Grant | 103,907 | — | 6/27/2024 |
| RA CAPITAL MANAGEMENT, L.P. | ▲ Buy | Grant | 973,000 | — | 6/27/2024 |
| RA CAPITAL MANAGEMENT, L.P. | ▲ Buy | Open Market | 11,949,171 | $45.9M | 6/27/2024 |
| Emily Pimblett | ▼ Sell | Open Market | 1,245 | $9K | 6/20/2024 |
| Emily Pimblett | ▲ Buy | Option Exercise | 5,000 | — | 6/18/2024 |
| Morisset Valerie | ▲ Buy | Option Exercise | 17,847 | $4 | 4/5/2024 |
| Morisset Valerie | ▲ Buy | Option Exercise | 5,431 | $11 | 9/20/2023 |
| Morisset Valerie | ▲ Buy | Option Exercise | 15,297 | $3 | 9/20/2023 |
| Morisset Valerie | ▲ Buy | Option Exercise | 255,219 | $510 | 3/10/2023 |
| Morisset Valerie | ▲ Buy | Option Exercise | 61,191 | $12 | 3/10/2023 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
Climb Bio Shares Jump on Kidney Drug Dosing Data; Analysts Raise Targets
Climb Bio saw shares climb roughly 17% after its Phase 1 trial for the kidney disease drug CLYM116 produced data supporting a 12-week dosing schedule for IgA nephropathy patients. The positive results prompted several analysts to raise their price targets, with targets now ranging from $25 to $32 per share. The stock has gained an extraordinary 1,300% over the past 17 months but recently experienced a pullback from those levels, suggesting profit-taking activity following the surge.
Climb Bio Shares Jump on Kidney Drug Dosing Data; Analysts Raise Targets. Climb Bio saw shares climb roughly 17% after its Phase 1 trial for the kidney disease drug CLYM116 produced data supporting a 12-week dosing schedule for IgA nephropathy patients. The positive results prompted several analysts to raise their price targets, with targets now ranging from $25 to $32 per share. The stock has gained an extraordinary 1,300% over the past 17 months but recently experienced a pullback from those levels, suggesting profit-taking activity following the surge.